Our Insights Oncology, R&D Insights Anthony Iannacci 11/11/25 Oncology, R&D Insights Anthony Iannacci 11/11/25 How Equinox Group Models Drugs in R&D: The Case of Alecensa in 1L ALK+ NSCLC Read More Oncology Anthony Iannacci 4/11/22 Oncology Anthony Iannacci 4/11/22 Rybrevant and Exkivity: two highly innovative new therapies to treat EGFR Exon 20 Insertion positive mNSCLC Read More Oncology, R&D Insights Anthony Iannacci 4/2/20 Oncology, R&D Insights Anthony Iannacci 4/2/20 Finding the Right Price for a Drug across Multiple Indications; Learnings from Keytruda Read More
Oncology, R&D Insights Anthony Iannacci 11/11/25 Oncology, R&D Insights Anthony Iannacci 11/11/25 How Equinox Group Models Drugs in R&D: The Case of Alecensa in 1L ALK+ NSCLC Read More
Oncology Anthony Iannacci 4/11/22 Oncology Anthony Iannacci 4/11/22 Rybrevant and Exkivity: two highly innovative new therapies to treat EGFR Exon 20 Insertion positive mNSCLC Read More
Oncology, R&D Insights Anthony Iannacci 4/2/20 Oncology, R&D Insights Anthony Iannacci 4/2/20 Finding the Right Price for a Drug across Multiple Indications; Learnings from Keytruda Read More
